Avidity Partners Management LP 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 9:40 pm Sale | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Avidity Partners Management LP | 235,000 0.400% | -3,590,000 (-93.86%) | Filing |
| 2023-02-14 2:58 pm Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Avidity Partners Management LP | 3,825,000 8.200% | 720,000 (+23.19%) | Filing |
| 2022-09-16 10:16 am Purchase | 2022-09-15 | 13G | Akero Therapeutics, Inc. AKRO | Avidity Partners Management LP | 3,105,000 6.900% | 3,105,000 (New Position) | Filing |